Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBrinker Capital Investments, LLC
Latest Disclosed Ownership11,862 shares
Latest Disclosed Value $ 5,296,638
Brinker Capital Investments, LLC ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Brinker Capital Investments, LLC filed a 13F-HR form disclosing ownership of 11,862 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,296,857 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 12,151 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -2.38% during the quarter. The current value of the position is $5,300,297 USD.

Brinker Capital Investments, LLC has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 1 of underlying shares valued at $447 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,862 -289 -2.38 5,297 -3.85 0.0451
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,151 1,803 17.42 5,508 35.93 0.0404
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,348 -993 -8.76 4,052 -19.73 0.0314
2025-08-27 2025-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 11,341 1,768 18.47 5,049 8.77 0.0431
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,337 1,764 5,047 0.0432
2025-08-01 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,573 610 6.81 4,641 28.60 0.0455
2025-08-01 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,963 154 1.75 3,609 -11.89 0.0360
2025-07-31 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,809 -710 -7.46 4,097 -8.18 0.0408
2025-07-31 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,519 1,133 13.51 4,462 27.28 0.0471
2025-07-31 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,386 -1,623 -16.22 3,505 -16.43 0.0375
2025-07-31 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,009 -485 -4.62 4,195 14.94 0.0487
2025-07-31 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,494 -1,048 -9.08 3,649 -10.15 0.0441
2025-07-31 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,542 662 6.08 4,062 18.50 0.0433
2025-07-31 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,880 2,955 37.29 3,428 49.78 0.0423
2023-02-06 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,925 -1,258 -13.70 2,289 -13.95 0.0456
2022-11-01 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,183 -480 -4.97 2,659 -2.35 0.0550
2022-07-18 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,663 -3,718 -27.79 2,723 -22.02 0.0516
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,381 -43 -0.32 3,492 18.45 0.0537
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,424 2,301 20.69 2,948 31.43 0.0429
2021-11-08 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,123 0 0.00 2,243 0.00 0.0355
2021-08-03 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,123 36 0.32 2,243 -5.87 0.0297
2021-05-12 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,087 -11,596 -51.12 2,383 -55.55 0.0358
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,683 12,838 130.40 5,361 100.11 0.0829
2020-12-03 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,845 9,845 2,679 0.0458
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -72 -100.00 0 -100.00
2020-02-06 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 72 5 7.46 16 45.45 0.0005
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 67 -436 -86.68 11 -88.04 0.0004
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 503 229 83.58 92 84.00 0.0029
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 274 274 50 0.0016
2017-02-08 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -3 -100.00 0 0.0000
2016-11-10 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3 3 0.00 0 0.0000
2016-05-09 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -12 -100.00 0 -100.00
2016-02-11 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12 3 33.33 2 100.00 0.0001
2015-11-12 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9 9 1 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM Call 1 0 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.